Med Surg Report Sheet Templates

- Aggregation appear its eyes to transform the abandoned corpuscle analysis mural application non-viral, antigen-specific UltraCAR-T® library access -

- Basic abstracts from Phase I abstraction of PRGN-2009 AdenoVerse™ immunotherapy in HPV-associated cancers appearance access in allowed acknowledgment aloft again administering of PRGN-2009 monotherapy -

- Preclinical abstracts provided for new AdenoVerse immunotherapies in communicable ache -

GERMANTOWN, Md., Jan. 13, 2021 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical aggregation specializing in the development of avant-garde gene and corpuscle therapies to advance the lives of patients, today presented analytic and preclinical updates at the 39th Annual J.P. Morgan Healthcare Conference. Helen Sabzevari, PhD, President and CEO of Precigen, presented a arbitrary of 2020 analytic achievements and set alternating Precigen's analytic goals for 2021.

Precigen Logo (PRNewsfoto/Precigen, Inc.)

In accession to reviewing the latest analytic updates for Precigen's PRGN-3005 UltraCAR-T, PRGN-3006 UltraCAR-T, AG019 ActoBiotics™, the presentation included the afterward added announcements:

UltraCAR-T Library Approach: Precigen alien the Company's eyes for a new UltraCAR-T library access to transform the abandoned corpuscle analysis mural for blight patients. Precigen's ambition is to advance and validate a library of non-viral plasmids to ambition tumor-associated antigens. Enabled by architecture and accomplishment advantages of UltraCAR-T, accompanying with the capabilities of the UltraPorator™ system, Precigen is alive to empower blight centers to bear personalized, autologous UltraCAR-T analysis with brief accomplishment to any blight patient. Based on the patient's blight adumbration and biomarker profile, one or added non-viral plasmids would be alleged from the library to body a abandoned UltraCAR-T treatment. Afterwards antecedent treatment, this access has the abeyant to acquiesce for redosing of UltraCAR-T targeting the aforementioned or new tumor-associated antigen(s) based on the analysis acknowledgment and the changes in antigen announcement of the patient's tumor. Precigen believes that the aggregate of the avant-garde UltraVector® DNA architecture belvedere and the affluence of brief accomplishment gives this library access a proprietary advantage over acceptable T-cell therapies.

PRGN-2009 AdenoVerse Immunotherapy in HPV-associated Cancers: For the aboriginal time, Precigen provided basic abstracts for the advancing Phase I/II abstraction of the first-in-class PRGN-2009 AdenoVerse immunotherapy to amusement HPV-positive (HPV ) solid tumors. The Phase I abstraction is evaluating assurance and acknowledgment of PRGN-2009 abandoned (Arm A) and in aggregate with bintrafusp alfa, an investigational bifunctional admixture protein, (Arm B) in patients with HPV-associated cancers beneath a Cooperative Research and Development Agreement (CRADA) with the National Blight Institute (NCI).

Preclinical abstracts for two new AdenoVerse immunotherapies:

"In animosity of the challenges presented by the COVID-19 pandemic, Precigen has able all of the analytic milestones we set for ourselves in 2020," said Helen Sabzevari, PhD, President and CEO of Precigen, "I am appreciative of the aggregation and collaborators for their charge and beheading during this arduous time which fabricated accessible the connected advance of our differentiated analysis aimed at benefiting patients with astringent unmet needs."

Story continues

Precigen's J.P. Morgan presentation is accessible on the Aggregation website in the Contest & Presentations area at investors.precigen.com/events-presentations.

Precigen: Advancing Medicine with Precision™ Precigen (Nasdaq: PGEN) is a committed analysis and analytic date biopharmaceutical aggregation advancing the abutting bearing of gene and corpuscle therapies application attention technology to ambition the best burning and awkward diseases in our amount ameliorative areas of immuno-oncology, autoimmune disorders, and communicable diseases. Our technologies accredit us to acquisition avant-garde solutions for affordable biotherapeutics in a controlled manner. Precigen operates as an addition agent advanced a preclinical and analytic activity of well-differentiated altered therapies against analytic proof-of-concept and commercialization. For added advice about Precigen, appointment www.precigen.com or chase us on Twitter @Precigen and LinkedIn.

Trademarks Precigen, Advancing Medicine with Precision, UltraCAR-T, AdenoVerse, UltraVector, UltraPorator and ActoBiotics are trademarks of Precigen and/or its affiliates. Added names may be trademarks of their corresponding owners.

Cautionary Account Regarding Forward-Looking Statements Some of the statements fabricated in this columnist absolution are advanced statements. These advanced statements are based aloft the Company's accepted expectations and projections about approaching contest and about chronicle to plans, objectives, and expectations for the development of the Company's business, including the timing and advance of preclinical studies, analytic trials, analysis programs and accompanying milestones, the affiance of the Company's portfolio of therapies, and in accurate its CAR-T and AdenoVerse therapies. Although administration believes that the affairs and objectives reflected in or appropriate by these advanced statements are reasonable, all advanced statements absorb risks and uncertainties, including the achievability that the timeline for the Company's analytic trials ability be impacted by the COVID-19 pandemic, and absolute approaching after-effects may be materially altered from the plans, objectives and expectations bidding in this columnist release. The Aggregation has no obligation to accommodate any updates to these advanced statements alike if its expectations change. All advanced statements are especially able in their absoluteness by this cautionary statement. For added advice on abeyant risks and uncertainties, and added important factors, any of which could account the Company's absolute after-effects to alter from those independent in the advanced statements, see the area advantaged "Risk Factors" in the Company's best contempo Annual Report on Form 10-K and consecutive letters filed with the Securities and Exchange Commission.

About HPV-associated Cancers HPV infects the squamous beef that band the close surfaces of assertive organs and, consequently, best HPV-related cancers are a blazon of blight alleged squamous corpuscle carcinoma. Some cervical cancers appear from HPV infection of gland beef in the cervix and are referred to as adenocarcinomas.1 HPV-related cancers accommodate cervical, oropharyngeal, anal, penile, vaginal, and vulvar.1 Nearly 44,000 HPV-associated cancers action in the United States anniversary year. Of these, about 25,000 action in women and 19,000 action in men.2 HPV is advised amenable for added than 90% of anal and cervical cancers, about 70% of vaginal and vulvar cancers, and added than 60% of penile cancers.2 Contempo studies announce that about 70% of cancers of the oropharynx additionally may be accompanying to HPV.2

About Alternate Respiratory Papillomatosis (RRP) Alternate respiratory papillomatosis (RRP) is a rare, difficult-to-treat and sometimes baleful neoplastic ache of the high and lower respiratory tracts that is acquired by infection with HPV 6 or HPV 11.3-6 RRP is classified based on age of access as adolescent or adult. Juvenile-onset ache has an accident of 4 per 100,000 and adult-onset RRP has an accident of 2 to 3 per 100,000. There is no cure for RRP and the accepted standard-of-care is again endoscopic debulking with ablation or abatement of papillomatous lesions.5,6 Recurrence of papilloma afterwards surgical abatement is actual accepted and again procedures are appropriate to debulk and adviser the disease, which exposes patients to analgesic and surgical risks, and affecting distress. RRP anguish and bloodshed after-effects from the furnishings of papilloma accumulation on the articulate cords, trachea, and lungs, which may account articulation changes, stridor, airway occlusion, accident of lung volume, and/or post-obstructive pneumonia.7 Although rare, one to three percent of RRP cases can transform into invasive squamous corpuscle carcinoma.8,9

About Hepatitis B Hepatitis B is a vaccine-preventable alarmist infection acquired by the hepatitis B virus (HBV). Abiding HBV infection can account austere bloom problems, including alarmist damage, cirrhosis, alarmist cancer, and death.10 Alarmist infection acquired by HBV may advance to abiding infection and hepatocellular blight (HCC).11 There is currently no cure for abiding HBV infection. The all-around prevalence of HBV is 257 million12 and there is a US prevalence of 850,000.10

References 1 HPV and Cancer, National Institutes of Health2 HPV-Associated Blight Statistics, Centers for Ache Control and Prevention3 Mounts, P et al. (1982). "Viral analysis of juvenile- and adult-onset squamous papilloma of the larynx." Proc Natl Acad Sci U S A 79(17): 5425-54294 Smith, E et al. (1993). "Human papillomavirus infection in papillomas and nondiseased respiratory sites of patients with alternate respiratory papillomatosis application the polymerase alternation reaction." Arch Otolaryngol Head Neck Surg 119(5): 554-5575 Derkay, CS et al. (2008). "Recurrent respiratory papillomatosis: a review." Laryngoscope 118(7): 1236-12476 Derkay, CS et al. (2019). "Update on Alternate Respiratory Papillomatosis." Otolaryngol Clin North Am 52(4): 669-6797 Seedat, RY (2020). "Juvenile-Onset Alternate Respiratory Papillomatosis Diagnosis and Administration - A Developing Country Review." Pediatric Bloom Med Ther 11: 39-46.8 Dedo, HH et al. (2001). "CO(2) laser analysis in 244 patients with respiratory papillomas." Laryngoscope 111(9): 1639-16449 Silver, RD et al. (2003). "Diagnosis and administration of pulmonary alteration from alternate respiratory papillomatosis." Otolaryngol Head Neck Surg 129(6): 622-62910 Hepatitis B Questions and Answers for the Public, US Centers for Ache Control and Prevention11 Xie Y., (2017). "Hepatitis B Virus-Associated Hepatocellular Carcinoma." Adv Exp Med Biol12 Hepatitis B, World Bloom Organization

Cision

View aboriginal agreeable to download multimedia:http://www.prnewswire.com/news-releases/precigen-provides-pipeline-updates-at-the-39th-annual-jp-morgan-healthcare-conference-301207917.html

SOURCE Precigen, Inc.

Med Surg Report Sheet Templates - Med Surg Report Sheet Templates | Welcome for you to my personal blog, with this occasion I'm going to provide you with in relation to Med Surg Report Sheet Templates .